LLY — Eli Lilly and Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Eli Lilly and Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	PRESS
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	28,318	28,541	34,124	45,043	65,179
Cost of Revenue
Gross Profit	21,006	21,912	27,042	36,624	54,127
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	22,367	21,414	27,666	32,144	38,877
Operating Profit	5,952	7,127	6,458	12,899	26,302
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,156	6,806	6,555	12,680	25,731
Provision for Income Taxes
Net Income After Taxes	5,582	6,245	5,240	10,590	20,640
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	5,582	6,245	5,240	10,590	20,640
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,582	6,245	5,240	10,590	20,640
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7.8	8.16	10.1	16.1	26.6
Dividends per Share